Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 334 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+ - NCT06857214RecruitingPhase 1
GNC-038 antibody study for moderate to severe lupus
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06711887RecruitingPhase 3
Long-term extension study of ianalumab for lupus nephritis
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Orchard Park, New YorkAges 18–100 - NCT06661213Enrolling by invitationEarly Phase 1
Tapinarof cream for lupus skin lesions
This study tests if a cream called tapinarof can improve skin symptoms in people with chronic or subacute cutaneous lupus erythematosus (CLE). The goal is to see if it reduces redness, scaling, and thickness of active lesions.
Chicago, IllinoisAges 18 years+ - NCT06642402Recruiting
Studying lupus kidney disease using urine particles
This study looks at tiny particles in urine to better understand and monitor lupus-related kidney problems. It may help find better ways to track the disease without invasive biopsies.
KoldingAges 18 years+ - NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Avondale, ArizonaAges 16 years+ - NCT04449991Recruiting
Repeat kidney biopsy in new lupus kidney disease
This study looks at whether doing a planned second kidney biopsy about 12 months later helps doctors understand and guide treatment for people with newly diagnosed lupus nephritis. You may be put on standard lupus-kidney medications, and the main “test” is the repeat biopsy timing.
StockholmAges 18 years+ - NCT06551389Recruiting
Lupus follow-up study at Brest Hospital
This study follows people with systemic lupus erythematosus (an autoimmune disease) who are seen in a special clinic. It aims to track their health over time.
BrestAges 18 years+ - NCT06535412RecruitingPhase 1/Phase 2
Study of IMC-002 for active lupus
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
BeijingAges 18–65 - NCT05698173Recruiting
Study of lupus and accelerated aging
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
BordeauxAges 18–60 - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06475742Enrolling by invitationPhase 3
Long-term safety of cenerimod in lupus patients
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Aurora, ColoradoAges 18–75 - NCT06458075Recruiting
Improving communication and medication adherence in lupus
This study tests whether helping lupus patients and their doctors communicate better leads to taking medications more consistently. Participants will have their doctor visits recorded and use a phone app to track their medicines.
Durham, North CarolinaAges 18–90 - NCT06400537RecruitingPhase 1
A-319 for active or tough-to-treat lupus (SLE)
This study tests a new drug called A-319 for people whose lupus (SLE) is active or hasn't improved with current treatments. The goal is to see if A-319 can help control lupus better.
Wuhan, HubeiAges 18–60 - NCT06308770Recruiting
Online group program for lupus fatigue
This trial tests a new online group program to help people with lupus manage chronic fatigue. Participants are randomly assigned to either the program or standard care, and all complete questionnaires online.
EdinburghAges 18–85 - NCT06232304Recruiting
Program for young people with childhood lupus
This study tests a program to help teenagers and young adults with childhood-onset lupus manage symptoms like fatigue, sadness, or pain. It aims to improve daily life and well-being.
Birmingham, AlabamaAges 12–22 - NCT05859191Recruiting
Study of immune cell markers in people with lupus
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
ToursAges 18 years+ - NCT01266915Recruiting
Cutaneous lupus skin disease registry study
This study builds a registry (a protected medical record) of people with cutaneous lupus and/or systemic lupus that affects the skin. It gathers skin exam information and may include a skin biopsy and blood tests to better understand these conditions.
Dallas, TexasAges 18 years+ - NCT05835310RecruitingPhase 3
IV anifrolumab for active lupus in children
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
Phoenix, ArizonaAges 5–17 - NCT05799378RecruitingPhase 3
Stopping hydroxychloroquine in older adults with stable lupus
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
Los Angeles, CaliforniaAges 55 years+ - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90 - NCT05538208RecruitingPhase 2
Children with lupus kidney inflammation using mycophenolate
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
San Francisco, CaliforniaAges 8–20 - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 334 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.